

Supplemental Table S2. Baseline mean concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in all participants and in subgroups stratified by selected baseline characteristics of study participants by treatment status (GTE or placebo), the Minnesota Green Tea Trial, 2009-2015

Stratifying variables at baseline	ALT (U/L), mean (95% CI)			AST (U/L), mean (95% CI)		
	Placebo	GTE	<i>P</i> *	Placebo	GTE	<i>P</i> *
Mean enzyme levels at baseline	18.0 (17.5-18.7)	17.6 (17.0-18.7)	0.25	20.7 (20.2-21.2)	20.0 (19.6-20.4)	0.04
Mean enzyme levels within stratified categories						
BMI (kg/m ²)						
<25	17.5 (16.0- 18.9)	17.6 (16.1-19.0)	0.85	21.3 (20.2-22.4)	20.6 (19.6-21.7)	0.16
25-<30	18.9 (17.4-20.4)	18.4 (16.8-20.0)	0.47	20.6 (19.5-21.8)	20.1 (18.8-21.2)	0.32
≥30	20.9 (18.7-23.2)	17.8 (15.7-19.8)	0.01	20.6(18.9-22.4)	19.4 (17.9-21.0)	0.23
<i>P</i> *	0.01	0.46		0.39	0.21	
Current alcohol drinker						
No	19.1 (17.2-20.9)	17.6 (15.8-19.4)	0.15	22.4 (21.0-23.8)	19.7 (18.4-21.1)	0.001
Yes	18.3 (16.9-19.6)	18.0 (16.6-19.3)	0.55	20.6 (19.6-21.6)	20.3 (19.3-21.3)	0.42
<i>P</i> *	0.34	0.59		0.01	0.36	
Baseline blood cholesterol level (mg/dl)						
<200	18.5 (17.0-20.1)	18.0 (16.5-19.5)	0.47	21.0 (19.8-22.2)	20.2 (19.1-21.4)	0.16
200-239	18.2 (16.7-19.7)	18.3 (16.7-19.8)	0.90	21.0 (19.9-22.2)	20.4 (19.2-21.6)	0.24
>240	17.5 (15.4-19.5)	15.8 (13.8-17.9)	0.18	20.3 (18.8-21.9)	19.2 (17.6-20.8)	0.24
<i>P</i> *	0.53	0.05		0.60	0.30	
Baseline blood triglyceride level (mg/dl)						
<150	17.9 (16.6-19.3)	17.6 (16.2-18.9)	0.49	21.1 (20.0-22.1)	20.1 (19.0-21.1)	0.01
≥150	19.8 (17.7-21.9)	19.7 (17.4-22.0)	0.93	19.7 (18.1-21.3)	20.8 (19.1-22.6)	0.29
<i>P</i> *	0.05	0.06		0.07	0.37	
Current use of aspirin						
No	18.3 (16.9-19.7)	17.9 (16.5-19.2)	0.37	21.1 (20.0-22.1)	20.3 (19.3-21.4)	0.06
Yes	18.6 (17.0-20.2)	18.1 (16.5-19.8)	0.62	20.7 (19.5-21.9)	20.2 (18.9-21.4)	0.39
<i>P</i> *	0.72	0.68		0.50	0.74	
Current use of non-aspirin NSAIDs						
No	19.2 (17.7-20.8)	17.0 (15.4-18.6)	0.003	21.1 (19.9-22.3)	20.3 (19.1-21.5)	0.18
Yes	18.0 (16.6-19.3)	18.4 (17.0-19.7)	0.42	20.9 (19.8-21.9)	20.3 (19.2-21.3)	0.13
<i>P</i> *	0.05	0.03		0.68	0.94	

(Supplemental Table S2 continued)

	ALT (U/L), mean (95% CI)			AST (U/L), mean (95% CI)		
	Placebo	GTE	<i>P</i> *	Placebo	GTE	<i>P</i> *
Current use of acetaminophen						
No	18.7 (17.3-20.0)	18.1 (16.7-19.5)	0.26	21.0 (20.0-22.0)	20.3 (19.3-21.4)	0.07
Yes	17.7 (16.0-19.3)	17.6 (16.0-19.2)	0.95	20.8 (19.5-22.0)	20.2 (19.0-21.4)	0.36
<i>P</i> *	0.14	0.48		0.62	0.81	
Current use of statin						
No	17.9 (16.6-19.3)	17.3 (15.9-18.6)	0.18	20.8 (19.8-21.8)	19.8 (18.8-20.8)	0.01
Yes	19.6 (17.9-21.3)	19.8 (18.1-21.5)	0.84	21.2 (19.9-22.5)	21.6 (20.3-22.9)	0.57
<i>P</i> *	0.03	0.001		0.47	0.002	

CI, confidence interval; BMI, body mass index; GTE, green tea extract; NSAIDs, non-steroidal anti-inflammatory drugs.

*2-sided *P* values were derived from generalized linear models comparing the baseline liver enzymes (ALT or AST) between treatment groups, or between different categories of stratifying variable within placebo/GTE group after adjustments for age, smoking status and level of education.